BN80927 in Patients With Advanced Malignant Solid Tumors
The purpose of this study was to determine the maximum tolerated dose and the recommended dose of BN80927 in patients with advanced malignant solid tumors.
BN80927 in Patients With Advanced Malignant Solid Tumors
- 24 July 2024 - 1 mins read
The purpose of this study was to determine the maximum tolerated dose and the recommended dose of BN80927 in patients with advanced malignant solid tumors.
Related Clinical Trials
24 July 2024
1 mins read
A study to evaluate the effect of phenytoin or itraconazole on the circulating levels of IPN60130 in healthy adult participants
24 July 2024
1 mins read
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva...
24 July 2024
1 mins read
A study to assess whether adding maintenance cabozantinib (XL184) to best supportive care helps children, adolescents and young adults with osteosarcoma.
24 July 2024
2 mins read
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults
24 July 2024
2 mins read
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults
24 July 2024
1 mins read
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
24 July 2024
2 mins read
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
24 July 2024
2 mins read
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
24 July 2024
1 mins read
Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
24 July 2024
1 mins read